Subject secondary prevention

In view of the perceived benefit of aspirin in the secondary prevention of stroke and myocardial infarction, two large trials involving physicians as subjects were initiated to study the effect of aspirin in the primary prevention of arterial thrombosis. In the American study, 22,000 volunteers (age 40 to 84 years) were randomly assigned to take 325 mg of aspirin every other day or placebo. The trial was halted early, after a mean follow-up of 5 years, when a 45% reduction in the incidence of myocardial infarction and a 72% reduction in the incidence of fatal myocardial infarction were noted with aspirin treatment. However, total mortality was reduced only 4% in the aspirin group, a difference that was not statistically significant, and there was a trend for a greater risk of hemorrhagic stroke with aspirin. Thus, the prophylactic use of aspirin in an apparently healthy population is not recommended at this time, unless there are risk factors for cardiovascular disease. 

Sources Subject to Prevention of Significant Deterioration (PSD) Sources subject to PSD regulations (40 CFR, Sec. 52.21) are major stationary sources and major modifications located in attainment areas and unclassified areas. A major stationary source was defined as any source listed in Table 22-4 with the potential to emit 100 tons per year or more of any pollutant regulated under the Clean Air Act (CAA) or any other source with the potential to emit 250 tons per year or more of any CAA pollutant. The potential to emit is defined as the maximum capacity to emit the pollutant under applicable emission standards and permit conditions (after application of any air pollution control equipment) excluding secondary emissions. A major modification is defined as any physical or operational change of a major stationary source producing a significant net emissions increase of any CAA pollutant (see Table 22-5). 

More controversial is the extent to which primary prevention (treatment of clinically unaffected patients with moderate elevation of cholesterol levels) should include drugs, and whether secondary prevention should ever start with drugs rather than diet. Dietary treatment can lower cholesterol levels in committed subjects, and is obviously less costly than drug treatment. Unforhmately numerous studies have shown that over any substantial period of time (e.g. one year) diet has no clinically significant influence on plasma cholesterol and the wait for diet to have an effect often results in patients being lost from hospital follow-up after their initial myocardial infarction. Evidence comes from the WOSCOPS stud) in which pravastatin 40 mg/day and placebo were compared in 6590 men age 50-70 with LDL cholesterol 4-6 mmol/1 pravastatin reduced coronary heart disease (fatal and nonfatal events) by 31%. The authors estimated that treatment of 1000 such subjects each year would prevent 20 myocardial infarctions. Concerns that primary prevention could have a net adverse outcome (that cholesterol reduction increased the risk of cancer or violent deaths) have been laid to rest by a number of outcome trials. 

The Coronary Drug Project (CDP) was a placebo-controlled secondary prevention study involving 1110 men randomized to niacin and 2789 randomized to placebo. The average daily niacin dose was 2000 mg and subjects were followed for six years. The niacin group experienced a 26% reduction in non-fatal myocardial infarctions and 24% reduction in cerebrovascular events (P <0.05 in each case) (Coronary Drug Project 1975). A 15-year follow-up study demonstrated an 11% total mortality reduction in subjects originally treated with niacin (P=0.0004) (Canner et al. 1986). 

Table 4 Summary of large intervention trials >1000 subjects) investigating the role of antioxidants and cancer in secondary prevention ...

Secondary prevention defined as subjects with documented cancer including nonmelanoma skin cancer (although some of the primary prevention trials did not exclude those with nonmelanoma skin cancer at baseline). 

Alkylation reactions are subject to the same constraints that affect all Sn2 reactions (Section 11.3). Thus, the leaving group X in the alkylating agent R—X can be chloride, bromide, iodide, or tosylate. The alkyl group R should be primary or methyl, and preferably should be allylic or benzylic. Secondary halides react poorly, and tertiary halides don t react at all because a competing E2 elimination of HX occurs instead. Vinylic and aryl halides are also unreactive because backside approach is sterically prevented. 

The thin-wall bellows element should be designed for membrane stresses to conform to code-allowable stresses. The sum of membrane and secondary bending stresses should not exceed 1.5 times the yield stress in order to prevent the collapse of the corrugations caused by pressure. Bellows subjected to external pressure can be analyzed in a manner similar to a cylinder, utilizing an equivalent moment of inertia. The fatigue life can be estimated based on the sum of deflections and pressure stresses as compared to S/N curves based on bellows test data or using the curves in B31.3 Appendix X, Metal Bellows Expansion Joints. Formulas for the stress analysis of bellows are available in the Expansion Joints Manufacturing Association (EJMA) Standards (37). 

---